Eapen Rohan, Okoye Cynthia, Stubbs Christopher, Schimpl Marianne, Tischer Thomas, Fisher Eileen J, Zacharopoulou Maria, Ferrer Fernando, Barford David, Spring David R, Lindon Catherine, Phillips Christopher, Itzhaki Laura S
Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom.
AstraZeneca, Cambridge, United Kingdom.
Elife. 2025 Sep 1;14:RP104238. doi: 10.7554/eLife.104238.
E3 ubiquitin ligases engage their substrates via 'degrons' - short linear motifs typically located within intrinsically disordered regions of substrates. As these enzymes are large, multi-subunit complexes that generally lack natural small-molecule ligands and are difficult to inhibit via conventional means, alternative strategies are needed to target them in diseases, and peptide-based inhibitors derived from degrons represent a promising approach. Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase-promoting complex/cyclosome (APC/C) that is essential in mitosis and consequently of interest as an anti-cancer target. APC/C engages substrates via degrons that include the 'destruction box' (D-box) motif. We used a rational design approach to construct binders containing unnatural amino acids aimed at better filling a hydrophobic pocket that contributes to the D-box binding site on the surface of Cdc20. We confirmed binding by thermal-shift assays and surface plasmon resonance and determined the structures of a number of the Cdc20-peptide complexes. Using a cellular thermal shift assay, we confirmed that the D-box peptides also bind to and stabilise Cdc20 in the cell. We found that the D-box peptides inhibit ubiquitination activity of APC/C and are more potent than the small-molecule inhibitor Apcin. Lastly, these peptides function as portable degrons capable of driving the degradation of a fused fluorescent protein. Interestingly, we find that although inhibitory activity of the peptides correlates with Cdc20-binding affinity, degradation efficacy does not, which may be due to the complex nature of APC/C regulation and effects of degron binding of subunit recruitment and conformational changes. Our study lays the groundwork for the further development of these peptides as molecular therapeutics for blocking APC/C as well as potentially for harnessing the APC/C for targeted protein degradation.
E3泛素连接酶通过“降解基序”与底物结合,这些短线性基序通常位于底物的内在无序区域内。由于这些酶是大型多亚基复合物,通常缺乏天然小分子配体,且难以通过传统方法抑制,因此需要替代策略来在疾病中靶向它们,而源自降解基序的基于肽的抑制剂是一种很有前景的方法。在这里,我们探索Cdc20的肽抑制剂,Cdc20是E3泛素连接酶后期促进复合物/细胞周期体(APC/C)的底物识别亚基和激活剂,在有丝分裂中至关重要,因此作为抗癌靶点备受关注。APC/C通过包括“破坏框”(D框)基序的降解基序与底物结合。我们采用合理设计方法构建了含有非天然氨基酸的结合物,旨在更好地填充一个疏水口袋,该口袋有助于Cdc20表面的D框结合位点。我们通过热位移分析和表面等离子体共振证实了结合,并确定了一些Cdc20-肽复合物的结构。使用细胞热位移分析,我们证实D框肽也能在细胞中与Cdc20结合并使其稳定。我们发现D框肽抑制APC/C的泛素化活性,并且比小分子抑制剂Apcin更有效。最后,这些肽作为可携带的降解基序,能够驱动融合荧光蛋白的降解。有趣的是,我们发现尽管肽的抑制活性与Cdc20结合亲和力相关,但降解效率并非如此,这可能是由于APC/C调节的复杂性质以及降解基序结合对亚基募集和构象变化的影响。我们的研究为进一步开发这些肽作为阻断APC/C的分子疗法以及潜在地利用APC/C进行靶向蛋白质降解奠定了基础。